Group 1 - The Sci-Tech 50 Index opened lower on November 26 but later rose significantly, closing at 1315.04 points with a gain of 0.99% and a trading volume of approximately 57.58 billion yuan [1] - The Sci-Tech Comprehensive Index also increased by 0.83%, closing at 1560.57 points with a total trading volume of about 182.8 billion yuan [2] - Excluding suspended stocks, the remaining 589 stocks on the Sci-Tech board showed an average decline of 0.15% with an average turnover rate of 2.66% [2] Group 2 - Semiconductor and biopharmaceutical stocks were notably active, while aviation and software service stocks experienced the largest declines [2] - Individual stock performance included Mingwei Electronics, Changguang Huaxin, Jindike, and Dongxin Co., which all hit the daily limit up, while Kangwei Century saw the largest drop at 10.78% [2] - In terms of trading volume, Hanwujing led with 11.89 billion yuan, while ST Guandian had the lowest at 1.027 million yuan [2] Group 3 - The turnover rate for Aerospace Huanyu was the highest at 31.51%, while Weigao Orthopedics had the lowest at 0.18% [3]

11月21日，威高骨科跌3.62%，成交额4814.93万元。两融数据显示，当日威高骨科获融资买入额914.95 万元，融资偿还1583.36万元，融资净买入-668.41万元。截至11月21日，威高骨科融资融券余额合计 1.42亿元。 融资方面，威高骨科当日融资买入914.95万元。当前融资余额1.42亿元，占流通市值的1.25%，融资余 额超过近一年80%分位水平，处于高位。 融券方面，威高骨科11月21日融券偿还0.00股，融券卖出300.00股，按当日收盘价计算，卖出金额 8541.00元；融券余量5351.00股，融券余额15.23万元，超过近一年80%分位水平，处于高位。 责任编辑：小浪快报 资料显示，山东威高骨科材料股份有限公司位于山东省威海市旅游度假区香江街26号，成立日期2005年 4月6日，上市日期2021年6月30日，公司主营业务涉及骨科医疗器械的研发、生产和销售。主营业务收 入构成为：关节29.01%，脊柱28.99%，运动医学和组织修复19.11%，创伤16.64%，其他6.10%，其他 (补充)0.15%。 截至9月30日，威高骨科股东户数1.07万，较上期增加18.33%；人均流 ...

Core Insights - The 24th Chinese Orthopaedic Association (COA) conference showcased significant advancements in orthopedic technology, emphasizing the integration of robotics, navigation, imaging, and biomaterials under the theme "Digital Intelligence in Orthopedics" [2] - The conference attracted 20,188 registered participants and received 37,222 submissions, indicating a strong interest in orthopedic innovations [2] Group 1: Robotics and Navigation Systems - Surgical robots and navigation systems are expanding across various orthopedic fields, moving beyond joint surgeries to include spine, trauma, and sports medicine, focusing on precision and standardization [4] - Companies like Stryker, Tianzhihang, and others are presenting comprehensive orthopedic platforms that integrate imaging, navigation, and robotic arms, forming a closed-loop system for enhanced surgical outcomes [4] - The Trinity system by Tuo Dao Medical demonstrates a unified platform for rapid switching between surgical procedures, showcasing advancements in AI planning and real-time navigation [19] Group 2: Biomaterials and Bone Repair - The competition in bone repair and biomaterials is intensifying, with companies offering innovative solutions such as absorbable screws and 3D-printed bioceramics, focusing on osteogenic activity and infection resistance [4] - Smartbone and other manufacturers are introducing advanced materials that not only fill defects but also promote bone regeneration and integration [4] Group 3: Domestic Innovations - Domestic companies are accelerating the development of high-end joint prosthetics and key materials, with a focus on integrating materials, prosthetic design, and manufacturing processes [4] - The collaboration between local firms and international companies is shifting from product showcases to establishing standards and ecosystems, enhancing the overall orthopedic landscape [4] Group 4: Key Product Launches - Stryker highlighted its latest products, including the Mako robotic system, which integrates multiple surgical techniques for hip and knee replacements, enhancing precision and efficiency [5][7] - Rosenboht signed a strategic partnership with the Chinese University of Hong Kong to advance intelligent surgical technologies, aiming for more precise and minimally invasive orthopedic procedures [12][14] - The launch of the "Panshi Self-Pressing 3D Partition Bone Trabecular Biological Knee Prosthesis" by Jiashite Medical showcases advancements in mechanical stability and biological fixation [40][42] Group 5: Technological Integration - Companies are increasingly focusing on integrating AI and imaging technologies to enhance surgical precision and safety, as seen in the solutions presented by Meiya Optical and other firms [46][50] - The introduction of AR navigation systems by Linyan Medical represents a significant technological advancement, improving the visibility and accuracy of spinal surgeries [53][55] Group 6: Comprehensive Solutions - The conference highlighted the importance of comprehensive solutions that encompass preoperative planning, intraoperative guidance, and postoperative evaluation, as demonstrated by various exhibitors [4][60] - Companies like Weigao and others are showcasing integrated solutions that leverage digital technologies to enhance the entire orthopedic treatment process [100][102]

近日，威高骨科发布公告称，公司董事、总经理卢均强因工作调整辞去公司第三届董事会董事及总经理 职务。副总经理李进取将代行总经理职责，直至董事会选聘新任总经理。卢均强辞职后，将继续在公司 控股股东、实际控制人控制的企业内任职。 截至本公告披露日，卢均强先生通过威海弘阳瑞信息技术中心（有限合伙）持有公司0.10%的股份。卢 均强辞去公司董事和高管职务后，将继续严格遵守《上海证券交易所科创板股票上市规则》《上市公司 股东减持股份管理暂行办法》《上市公司董事和高级管理人员所持本公司股份及其变动管理规则》等规 定及其所作的相关承诺。 (编辑：杨燕 林辰)关键字： 医疗 （威高骨科公告） ...

Core Points - The company announced the resignation of its General Manager, Lu Junqiang, due to work adjustments, effective immediately upon submission of his resignation [1][2] - Vice General Manager, Li Jinqiu, will temporarily assume the responsibilities of the General Manager until a new appointment is made by the board [1] - Lu Junqiang will continue to hold a position in a company controlled by the major shareholder and actual controller [1] Company Governance - Lu Junqiang held 0.10% of the company's shares through Weihai Hongyang Rui Information Technology Center (Limited Partnership) [2] - The company will follow legal procedures to complete the election of a new director and the appointment of a new General Manager in accordance with relevant laws and regulations [2] - The board expressed gratitude for Lu Junqiang's contributions to the company's development during his tenure [2]

（文章来源：证券日报） 证券日报网讯 11月19日晚间，威高骨科发布公告称，公司董事会于11月19日收到公司董事、总经理卢 均强先生递交的书面辞职申请。因工作调整原因，卢均强先生不再担任公司第三届董事会董事、总经理 职务，由副总经理李进取先生代行总经理职责，直至董事会选聘新任总经理。卢均强先生将继续在公司 控股股东、实际控制人控制的企业内任职。 ...

北京商报讯（记者 丁宁）11月19日晚间，威高骨科（688161）发布公告称，公司董事会于11 月19日收 到公司董事、总经理卢均强递交的书面辞职申请。因工作调整原因，卢均强不再担任公司第三届董事会 董事、总经理职务，由副总经理李进取代行总经理职责，直至董事会选聘新任总经理。卢均强将继续在 公司控股股东、实际控制人控制的企业内任职。 ...

证券代码：688161 证券简称：威高骨科 公告编号：2025-045 截至本公告披露日，卢均强先生通过威海弘阳瑞信息技术中心（有限合伙） 持有公司 0.10%的股份。卢均强先生辞去公司董事和高管职务后，将继续严格遵 守《上海证券交易所科创板股票上市规则》《上市公司股东减持股份管理暂行办 法》《上市公司董事和高级管理人员所持本公司股份及其变动管理规则》等规定 及其所作的相关承诺。 公司将根据《中华人民共和国公司法》《上海证券交易所科创板股票上市规 则》及《公司章程》等相关规定，按照法定程序尽快完成公司董事的选举及总经 理的选聘等相关工作。 卢均强先生在担任公司董事、总经理期间，恪尽职守、勤勉尽责，为公司规 范运作和长远发展发挥了重要作用，公司及公司董事会对卢均强先生任职期间为 公司发展做出的贡献表示衷心感谢。 特此公告。 山东威高骨科材料股份有限公司董事会 山东威高骨科材料股份有限公司 关于公司董事、总经理工作调整的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 山东威高骨科材料股份有限公司（以下简称"公司"）董事会 ...

Market Overview - The net outflow of main funds in the Shanghai and Shenzhen markets reached 40.955 billion yuan, with the Sci-Tech Innovation Board experiencing a net outflow of 5.791 billion yuan [1] - A total of 178 stocks saw net inflows, while 415 stocks experienced net outflows [1] Sci-Tech Innovation Board Performance - On the Sci-Tech Innovation Board, 93 stocks rose, while 496 stocks fell, with one stock, He Xin Instrument, hitting the daily limit down [1] - C Hengkun, listed for 5 days, had a significant drop of 2.44% [1] Fund Flow Analysis - Among the 178 stocks with net inflows, five stocks had inflows exceeding 100 million yuan, led by Yuanjie Technology with a net inflow of 316 million yuan [2] - Other notable inflows included Changguang Huaxin and Yingshi Innovation, with net inflows of 144 million yuan and 113 million yuan, respectively [2] Continuous Fund Flow - 46 stocks showed continuous net inflows for more than three trading days, with Weigao Orthopedics leading at 10 consecutive days of inflow [2] - Conversely, 202 stocks experienced continuous net outflows, with Zhixiang Jintai leading at 17 consecutive days of outflow [2] Top Fund Inflows - The top stocks by net inflow included: - Yuanjie Technology: 315.73 million yuan, 10.22% inflow rate, 3.56% increase [2] - Changguang Huaxin: 144.31 million yuan, 11.14% inflow rate, 2.00% increase [2] - Yingshi Innovation: 113.72 million yuan, 21.35% inflow rate, 4.26% increase [2] Notable Outflows - The stocks with the highest net outflows included: - SMIC: 800.2 million yuan, 1.42% decrease [1] - Baiwei Storage: 344 million yuan outflow [1] - Guodun Quantum: 263 million yuan outflow [1]

证券代码：688161 证券简称：威高骨科 公告编号：2025-044 山东威高骨科材料股份有限公司 2025年第二次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 本次会议是否有被否决议案：无 一、会议召开和出席情况 （三）出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及其持有表决权数量的情 况： ■ （四）表决方式是否符合《公司法》及公司章程的规定，股东会主持情况等。 1、议案名称：《关于公司拟聘请会计师事务所的议案》 本次股东会由董事会召集，采用现场投票和网络投票相结合的方式召开，会议由董事长陈敏女士主持， 本次会议的召集、召开方式符合《公司法》、《证券法》、《公司章程》的规定。 （五）公司董事和董事会秘书的出席情况 1、公司在任董事9人，出席9人； 2、董事会秘书林青女士出席会议； 3、公司高管、见证律师列席本次会议。 二、议案审议情况 （一）非累积投票议案 审议结果：通过 表决情况： ■ （二）涉及重大事项，应说明5%以下股东的表决情况 ■ （三）关于议案表决的 ...